GILD vs. NVO: Gilead Sciences vs. Novo Nordisk Stock Comparison

Company Profile

Gilead Sciences (GILD) and Novo Nordisk (NVO) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but GILD is classified in Biotechnology while NVO is classified in Pharmaceuticals.

Gilead Sciences (GILD) trades as ordinary local shares, while Novo Nordisk (NVO) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Gilead Sciences (GILD) reports a negative ROE of -22.45%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Novo Nordisk (NVO) reports 58.38%, ranking against industry peers normally.

Gilead Sciences (GILD) reports a negative net margin of -12.46%, usually indicating a net loss over the period. Meanwhile Novo Nordisk (NVO) reports 33.92%, ranking against industry peers normally.

Both Gilead Sciences (GILD) at 42.43% and Novo Nordisk (NVO) at 40.05% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Gilead Sciences (GILD) at 2.39% and Novo Nordisk (NVO) at 6.43% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Gilead Sciences (GILD) at 1,684.21% clears its industry range for EPS growth, a much stronger earnings trajectory than Novo Nordisk (NVO) at 1.77%, which is closer to a typical peer reading.

Growth Metrics

Financial Strength

Both Gilead Sciences (GILD) at 1.38 and Novo Nordisk (NVO) at 0.85 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Novo Nordisk (NVO) at 0.62 is near its industry mid-range for debt-to-equity ratio, while Gilead Sciences (GILD) at 2.02 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Both Gilead Sciences (GILD) at 1.94% and Novo Nordisk (NVO) at 29.03% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

Both Gilead Sciences (GILD) at 43.46% and Novo Nordisk (NVO) at 45.36% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Novo Nordisk (NVO) trades at 10.18 times trailing earnings, ranked against its peers, while Gilead Sciences (GILD) has no P/E ratio this period.

Novo Nordisk (NVO) at 0.53 sits in the cheaper P/S ratio quartile while Gilead Sciences (GILD) at 6.68 prices around its industry’s middle — NVO costs less per dollar of sales, though read it alongside growth and margins.

Novo Nordisk (NVO) at 5.43 sits near its industry’s typical P/B ratio, while Gilead Sciences (GILD) at 15.88 prices above its benchmark range — GILD looks rich relative to book.

Valuation Metrics